Jeffrey Zhong discusses a retrospective UNITE consortium analysis of dose modifications of enfortumab vedotin plus pembrolizumab in 360 patients with advanced urothelial carcinoma ...
Susan Halabi presents a ctDNA-based prognostic model for radiographic progression-free survival in mCRPC patients receiving first-line androgen receptor pathway inhibitors. The mo ...
AUA 2026, BCG naive and BCG-Exposed High-Risk Non–muscle Invasive Bladder Cancer, Intravesical MK-3120, anti–Nectin-4 monoclonal antibody, MK-3120 I-VESIC.
(UroToday.com) The 2026 SESAUA annual meeting featured the Gee-Dineen lecture series and a presentation by Dr. Andrew Harris discussing the state of the Urology workforce. Dr. Harris started his ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results